With acalabrutinib, circulating CD4 T cell counts are not changed, while CD8 T cell counts are decreased after 15 cycles of treatment in CLL patients (Byrd et al., 2016). This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.